July 26, 2018 News by Diogo Pinto Brain Changes in CIS Patients May Be to Blame for Depression, Reduced Quality of Life, Study Suggests Changes in the brains of patients with clinically isolated syndrome (CIS), the first clinical presentation of multiple sclerosis (MS), may be partly responsible for depressive symptoms and reduced quality of life in these patients, a study shows. The study with that finding, āHealth-related quality of life, neuropsychiatric…
July 24, 2018 News by Ana Pena PhD Cerebrospinal Fluid Neurofilament Predicts CIS and RRMS Progression, Study Contends Cerebrospinal fluid levels of neurofilament light chain, a protein associated with nerve cell damage, can predict disease progression in people with clinical isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS), a Swedish study found. Higher levels…
May 14, 2018 News by Jose Marques Lopes, PhD B-Cell Changes May Predict Conversion from Clinically Isolated Syndrome to MS, Study Suggests B-cell alterations in peripheral blood may predict the conversion of clinically isolated syndrome (CIS) to multiple sclerosis (MS), a recent study suggests. Conducted in Turkey, the study, āPeripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis,ā was published in…
January 25, 2018 Columns by Tamara Sellman The MS Alphabet: Provigil, Progression, Plantar Reflex, and Other ‘P’ Words (Part 4 of 7) Editorās note: Tamara Sellman continues her occasional series on the MS alphabet with this column referencing terms starting with the letter P. This post comes fourth in a series of seven. Symptoms of MS Postural tremor Tremors (specifically, cerebellar tremors) are a common symptom of MS. A…
October 27, 2017 News by Patricia Inacio, PhD #MSParis2017 – Multiple Sclerosis Can Stay Mild for Decades, 30-year British Study Shows After the first round of symptoms,Ā multiple sclerosis can stay mild without causing major problems for decades, a 30-year British study indicates. Karen K.Ā Chung of theĀ University College London Institute of NeurologyĀ discussed the findings atĀ the ECTRIMS-ACTRIMS meetingĀ in Paris, which started Oct. 25 and runs until 28. His presentation was titled āDoes…
October 26, 2017 News by Patricia Silva, PhD #MSParis2017 – Types of Brain and Spinal Cord Lesions Help Determine if MS Develops, Study Reports The types of brain and spinal cord inflammation patches that occur in a precursor condition to multiple sclerosis help determine whether a person develops MS in the next 15 years, a British neurologist reported today. Wallace J. Brownlee of the University College London Institute of NeurologyĀ made the observation in…
June 15, 2017 News by Janet Stewart, MSc High Salt Consumption Has No Effect on Multiple Sclerosis Symptoms or Prognosis, Study Finds Eating a diet high in salt won’t worsen or speed up multiple sclerosis (MS) symptoms, concludes a study of MS patients with clinically isolated syndrome (CIS).Ā That contradicts earlier studies by researchers from Argentina, Vermont and elsewhere who warned of a possible link between high sodium consumption and MS. The…
April 13, 2017 Columns by Tamara Sellman The MS Alphabet: CIS, Copaxone, Contracture and More ‘C’ Terms (Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this secondĀ of three partsĀ on terms starting with the letter “C.”) When it comes to multiple sclerosis, mastering an understanding of the disease means you need to mind your Ps and Qs, dot your Is, cross your Ts,…
October 20, 2016 News by Alice MelĆ£o, MSc Relapses and Dislike of Needles Among Reasons MS Patients Stop Betaferon Treatment Multiple sclerosis (MS) patients with more advanced disease, as evidenced by disability, and those more frequent relapses or aversion to needles are among the groups of peopleĀ at higher risk of discontinuing Betaferon (interferon beta-1b) treatment, researchers report. These findings may help to alert clinicians toĀ those least likely to adhere to…
August 19, 2016 News by InĆŖs Martins, PhD MS Progression Slower in People Who Begin Betaseron Therapy at First Signs of Disease, 11-Year Study Says Relapsing multiple sclerosis patients who begin taking Betaferon/Betaseron (interferon beta-1b) immediately after the first MS-related neurologic symptoms appear mayĀ realize slower disease progression thanĀ those who delay treatment, according to aĀ study evaluating the therapy’sĀ effects over a decade in patients enrolledĀ inĀ aĀ Phase 3 clinical trial. The study, “The 11-year long-term follow-up…